Abstract
There is increasing evidence that the complexity of the retinal vasculature (measured as fractal dimension, Df) might offer earlier insights into the progression of coronary artery disease (CAD) before traditional biomarkers can be detected. This association could be partly explained by a common genetic basis; however, the genetic component of Df is poorly understood. We present here a genome-wide association study (GWAS) aimed to elucidate the genetic component of Df and to analyse its relationship with CAD. To this end, we obtained Df from retinal fundus images and genotyping information from ∼38,000 white-British participants in the UK Biobank. We discovered 9 loci associated with Df, previously reported in pigmentation, retinal width and tortuosity, hypertension, and CAD studies. Significant negative genetic correlation estimates endorse the inverse relationship between Df and CAD, and between Df and myocardial infarction (MI), one of CAD fatal outcomes. This strong association motivated us to developing a MI predictive model combining clinical information, Df, a CAD polygenic risk score and using a random forest algorithm. Internal cross validation evidenced a considerable improvement in the area under the curve (AUC) of our predictive model (AUC=0.770) when comparing with an established risk model, SCORE, (AUC=0.719). Our findings shed new light on the genetic basis of Df, unveiling a common control with CAD, and highlights the benefits of its application in individualised MI risk prediction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank Resource under project 788. This work is supported by the Medical Research Council grant (MR/N013166/1) to A.V.V; the Roslin Institute Strategic Programme Grant from the BBSRC (BBS/E/D/30002275 and BBS/E/D/30002276) to A.T; Health Data Research UK grants (references HDR-9004 and HDR-9003) to A.T; the Engineering and Physical Sciences Research Council (EPSRC) grant (EP/R029598/1, EP/T008806/1) to M.O.B; Fondation Leducq grant (17 CVD 03) to M.O.B, the European Union's Horizon 2020 research and innovation programme under grant agreement No 801423 to M.O.B; Diabetes UK grant (20/0006221) to M.O.B; Fight for Sight grant (5137/5138) to M.O.B; and British Heart Foundation and The Alan Turing Institute (which receives core funding under the EPSRC grant EP/N510129/1) as part of the Cardiovascular Data Science Awards Round 2 (SP/19/9/34812) to M.O.B. Support from NHS Lothian R&D and the Edinburgh Clinical Research Facility is acknowledged.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UKBiobank
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
